Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908687 · ClinicalTrials.gov registry record · Phase 2
A/H5N1/LT Dose Ranging Study
A Phase 2 study, sponsored by Intercell USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT00908687 is a Phase 2 study that has completed, run by Intercell USA. The registered enrollment target is 500 participants.
The verdict
NCT00908687, a Phase 2 study, has completed, sponsored by Intercell USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, blinded, clinical trial. Up to 500 eligible subjects will be enrolled and randomized in a 1:2:2:1:2:2 ratio into one of six groups, and vaccinated in this study. Subjects will receive an intramuscular injection of the influenza A/H5N1 (low or high dose) on Day 0 with or without a patch (low or high dose).
Interventions
- BIOLOGICAL A/H5N1
- BIOLOGICAL LT Adjuvant Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908687
The ClinicalTrials.gov registry entry for NCT00908687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intercell USA, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which A/H5N1 is the first listed.
NCT00908687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908687 about?
NCT00908687 is a clinical study titled "A/H5N1/LT Dose Ranging Study". This is a Phase 2, randomized, blinded, clinical trial. Up to 500 eligible subjects will be enrolled and randomized in a 1:2:2:1:2:2 ratio into one of six groups, and vaccinated in this study. Subjects will receive an intramuscular injection of the influenza A/H5N1 (low or high dose) on Day 0 with o...
What is the current status of trial NCT00908687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2009-05. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00908687?
The interventions under investigation include: A/H5N1 (BIOLOGICAL), LT Adjuvant Patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT00908687?
This trial is sponsored by Intercell USA, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.